{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:39:37Z","timestamp":1794440377429,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00262-021-03009-z","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T15:02:21Z","timestamp":1628348541000},"page":"689-703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"71","author":[{"given":"Xian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-an","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-7369","authenticated-orcid":false,"given":"Peihua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,7]]},"reference":[{"issue":"95","key":"3009_CR1","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL et al (2011) T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia. Sci Transl Med 3(95):95ra73","journal-title":"Sci Transl Med"},{"issue":"18","key":"3009_CR2","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Riviere I, Park JH et al (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18):4817\u20134828","journal-title":"Blood"},{"issue":"9967","key":"3009_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517\u2013528","journal-title":"Lancet"},{"issue":"224","key":"3009_CR4","doi-asserted-by":"publisher","first-page":"24425","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang XY et al (2014) Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):24425","journal-title":"Sci Transl Med"},{"issue":"5","key":"3009_CR5","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu EL et al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121(5):1822\u20131826","journal-title":"J Clin Invest"},{"issue":"16","key":"3009_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507\u20131517","journal-title":"N Engl J Med"},{"issue":"6","key":"3009_CR7","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C et al (2016) CD19 CAR-T cells of defined CD4+:CD8+composition in adult B cell ALL patients. J Clin Invest 126(6):2123\u20132138","journal-title":"J Clin Invest"},{"issue":"5","key":"3009_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M et al (2018) Long-Term Follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449\u2013459","journal-title":"N Engl J Med"},{"issue":"1","key":"3009_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Engl J Med 379(1):64\u201373","journal-title":"N Engl J Med"},{"issue":"16","key":"3009_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509\u20131518","journal-title":"N Engl J Med"},{"issue":"25","key":"3009_CR11","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C et al (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129(25):3322\u20133331","journal-title":"Blood"},{"issue":"5","key":"3009_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439\u2013448","journal-title":"N Engl J Med"},{"issue":"15","key":"3009_CR13","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV et al (2019) Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cell therapy. Blood 133(15):1652\u20131663","journal-title":"Blood"},{"issue":"1","key":"3009_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter D, Frey N, Wood PA, Weng YQ, Grupp SA et al (2018) Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol 11(1):35","journal-title":"J Hematol Oncol"},{"issue":"10","key":"3009_CR15","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","volume":"4","author":"X Zhang","year":"2020","unstructured":"Zhang X, Lu XA, Yang JF et al (2020) Efficacy and safety of anti-CD19 CAR-T cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv 4(10):2325\u20132338","journal-title":"Blood Adv"},{"key":"3009_CR16","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Acute Lymphoblastic Leukemia Version 1.2020 https:\/\/www.nccn.org\/"},{"issue":"4","key":"3009_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"key":"3009_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bcp.2017.09.007","volume":"147","author":"D Steinhilber","year":"2018","unstructured":"Steinhilber D, Marschalek R (2018) How to effectively treat acute leukemia patients bearing MLL-rearrangements. Biochem Pharmacol 147:183\u2013190","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"3009_CR19","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3390\/cells8111341","volume":"8","author":"O Britten","year":"2019","unstructured":"Britten O, Ragusa D, Tosi S, Kamel YM (2019) MLL-rearranged acute leukemia with t (4;11) (q21; q23)-Current treatment options is there a role for CAR-T cell therapy? Cells 8(11):1341","journal-title":"Cells"},{"issue":"10","key":"3009_CR20","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41591-018-0212-6","volume":"24","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Brentjens RJ (2018) Tumors evading CARs-the chase is on. Nat Med 24(10):1492\u20131493","journal-title":"Nat Med"},{"issue":"20","key":"3009_CR21","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S et al (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127(20):2406\u20132410","journal-title":"Blood"},{"issue":"2","key":"3009_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/leu.2010.253","volume":"25","author":"J Boer","year":"2011","unstructured":"Boer J, Yeung J, Ellu J et al (2011) The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors. Leukemia 25(2):321\u2013330","journal-title":"Leukemia"},{"issue":"1","key":"3009_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/leu.2016.202","volume":"31","author":"S Eldfors","year":"2017","unstructured":"Eldfors S, Kuusanm\u00e4ki H, Kontro M et al (2017) Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. Leukemia 31(1):51\u201357","journal-title":"Leukemia"},{"issue":"1","key":"3009_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10555-020-09848-z","volume":"39","author":"L Lenk","year":"2020","unstructured":"Lenk L, Alsadeq A, Schewe DM (2020) Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data. Cancer Metastasis Rev 39(1):173\u2013187","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"3009_CR25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2016.263","volume":"31","author":"A Stengel","year":"2017","unstructured":"Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C (2017) The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia 31(3):705\u2013711","journal-title":"Leukemia"},{"issue":"2","key":"3009_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/blood-2014-02-558833","volume":"124","author":"A Stengel","year":"2014","unstructured":"Stengel A, Schnittger S, Weissmann S et al (2014) TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood 124(2):251\u2013258","journal-title":"Blood"},{"issue":"4","key":"3009_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/jmcb\/mjy072","volume":"11","author":"X Zhou","year":"2019","unstructured":"Zhou X, Hao Q, Lu H (2019) Mutant p53 in cancer therapy-the barrier or the path. J Mol Cell Biol 11(4):293\u2013305","journal-title":"J Mol Cell Biol"},{"issue":"7","key":"3009_CR28","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1080\/10428194.2017.1375107","volume":"59","author":"KD Cummins","year":"2018","unstructured":"Cummins KD, Gill S (2018) Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse. Leuk Lymphoma 59(7):1539\u20131553","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3009_CR29","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","volume":"20","author":"MR Benmebarek","year":"2019","unstructured":"Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S (2019) Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci 20(6):1283","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3009_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","volume":"2","author":"L Labanieh","year":"2018","unstructured":"Labanieh L, Majzner RG, Mackall CL (2018) Programming CAR-T cells to kill cancer. Nat Biomed Eng 2(6):377\u2013391","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"3009_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ et al (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 24(1):20\u201328","journal-title":"Nat Med"},{"issue":"18","key":"3009_CR32","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1158\/1078-0432.CCR-19-0916","volume":"25","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Liu ZF, Wang X et al (2019) Treatment with humanized selective CD19CAR-T cells shows efficacy in highly treated B-ALL patients who have relapsed after receiving murine-based CD19CAR-T therapies. Clin Cancer Res 25(18):5595\u20135607","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3009_CR33","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3390\/ijms20061397","volume":"20","author":"J Bauer","year":"2019","unstructured":"Bauer J, Nelde A, Bilich T, Walz JS (2019) Antigen targets for the development of Immunotherapies in leukemia. Int J Mol Sci 20(6):1397","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3009_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40265-018-0863-0","volume":"78","author":"KK Ciombor","year":"2018","unstructured":"Ciombor KK, Goldberg RM (2018) Hypermutated tumors and immune checkpoint inhibition. Drugs 78(2):155\u2013162","journal-title":"Drugs"},{"issue":"5","key":"3009_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/MPH.0000000000001479","volume":"41","author":"A Taraseviciute","year":"2019","unstructured":"Taraseviciute A, Broglie L, Phelan R, Bhatt NS, Becktell K, Burke MJ (2019) What is the role of hematopoietic cell transplantation (HCT) for pediatric acute lymphoblastic leukemia (ALL) in the age of chimeric antigen receptor T-Cell (CART) therapy? J Pediatr Hematol Oncol 41(5):337\u2013344","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"3009_CR36","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/leu.2017.145","volume":"31","author":"J Pan","year":"2017","unstructured":"Pan J, Yang JF, Deng BP et al (2017) High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia 31(12):2587\u20132593","journal-title":"Leukemia"},{"issue":"3","key":"3009_CR37","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/sj.leu.2403283","volume":"18","author":"E Coustan-Smith","year":"2004","unstructured":"Coustan-Smith E, Gajjar A, Hijiya N et al (2004) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 18(3):499\u2013504","journal-title":"Leukemia"},{"issue":"9289","key":"3009_CR38","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S0140-6736(01)06355-3","volume":"358","author":"C Eckert","year":"2001","unstructured":"Eckert C, Biondi A, Seeger K et al (2001) Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358(9289):1239\u20131241","journal-title":"Lancet"},{"issue":"13","key":"3009_CR39","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1182\/blood-2013-10-534297","volume":"123","author":"MA Pulsipher","year":"2014","unstructured":"Pulsipher MA, Langholz B, Wall DA et al (2014) The addition of sirolimus to tacrolimus\/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children\u2019s Oncology Group\/Pediatric Blood and Marrow Transplant Consortium trial. Blood 123(13):2017\u20132025","journal-title":"Blood"},{"issue":"12","key":"3009_CR40","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA et al (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells. Cancer Discov 7(12):1404\u20131419","journal-title":"Cancer Discov"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03009-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03009-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03009-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T11:06:34Z","timestamp":1645095994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03009-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3009"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03009-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,7]]},"assertion":[{"value":"27 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xin-an Lu and Fei Wu are employees of Immunochina Pharmaceuticals Co., Ltd. Jianqiang Li and Dandan Chen are employees of Hebei Senlang Biotechnology, Xiangqun Li are employees of Doing Biomedical Co., Ltd, Zhongwei Xu are employees of Bioceltech Therapeutics Co., Ltd, and Shuqiang Liu are employees of Tianjin Mycure Medical Technology Co., Ltd. This study was partly sponsored by Immunochina Pharmaceuticals Co., Ltd. Hebei Senlang Biotechnology, Doing Biomedical Co., Ltd, Bioceltech Therapeutics Co., Ltd, and Tianjin Mycure Medical Technology Co., Ltd. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}